CODX
Co-Diagnostics, Inc.
There isn't enough reported data to score CODX yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CODX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CODX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CODX PE Valuation
CODX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CODX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CODX's losses to shrink, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CODX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$22.88 | +$6.82 |
| Q2 2026 | -$26.67 | +$7.83 |
| Q1 2026 | -$32.11 | +$2.99 |
| Q4 2025 | -$35.25 | +$1.95 |
| Q3 2025 | -$29.70 | +$11.40 |
| Q2 2025 | -$34.50 | +$3.00 |
| Q1 2025 | -$35.10 | +$4.20 |
| Q4 2024 | -$37.20 | -$1.20 |
CODX is still losing money, but less than at its worst: $22.88 per share over the past year, against $41.40 at its worst in late 2023.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CODX on earnings quality, reporting a profit while its opponent remains loss making.
CODX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $282.9K | +95% |
| Q2 2026 | $166.1K | +2% |
| Q1 2026 | $146K | +190% |
| Q4 2025 | $263.9K | +77% |
| Q3 2025 | $145.4K | -77% |
| Q2 2025 | $162.9K | -94% |
| Q1 2025 | $50.3K | -89% |
| Q4 2024 | $149.3K | -96% |
CODX's revenue is recovering but still below its 2021 peak: $282,881 last quarter, up 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2216% | +2608 points |
| Q2 2026 | -3732% | +1214 points |
| Q1 2026 | -6309% | +10701 points |
| Q4 2025 | -10057% | -2083 points |
| Q3 2025 | -4824% | -3228 points |
| Q2 2025 | -4946% | -4657 points |
| Q1 2025 | -17010% | -14817 points |
| Q4 2024 | -7974% | -7641 points |
CODX's operating margin was −2216% last quarter, up 2608 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CODX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CODX on profitability, with a higher operating margin.
CODX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.7M | +$280.7K |
| Q2 2026 | -$7.2M | +$1.5M |
| Q1 2026 | -$8M | +$848.8K |
| Q4 2025 | -$6.3M | +$2M |
| Q3 2025 | -$6M | +$1.4M |
| Q2 2025 | -$8.7M | -$3.4M |
| Q1 2025 | -$8.8M | +$55.5K |
| Q4 2024 | -$8.3M | -$3.1M |
CODX has burned cash in most quarters: −$27M over the past year, against −$32M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CODX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CODX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +46% | +2M shares |
| 1 year | +468% | +5.2M shares |
| 3 years | +547% | +5.3M shares |
| 5 years | +533% | +5.3M shares |
| Available history | +725% | +5.5M shares |
CODX has 6M diluted shares, up 468% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $159,673 |
| Q3 2023 | $166,326 |
| Q2 2023 | $555,734 |
| Q1 2023 | $482,196 |
| Q4 2022 | $1.2M |
| Q3 2022 | $10.4M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CODX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CODX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -7.7x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -1.9x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.4x | Net Cash |
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | -1.0x | Net Cash |
CODX has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CODX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.5 | Neutral |
| Stochastic | 0.9 | Oversold |
CODX's weekly RSI is 34 (neutral) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CODX PE vs Healthcare Sector
| Metric | CODX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CODX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CODX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.67 | 60% below |
| 20 week MA | $1.28 | 79% below |
| 50 week MA | $2.84 | 90% below |
| 100 week MA | $7.77 | 97% below |
| 200 week MA | $24.5 | 99% below |
CODX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CODX on trend strength, trading above more of its moving averages.
CODX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.8 | $325.2 | +1069% |
| 2021 | $325.2 | $282.3 | -13% |
| 2022 | $282.3 | $76.5 | -73% |
| 2023 | $76.5 | $39.9 | -48% |
| 2024 | $39.9 | $21.9 | -45% |
| 2025 | $21.9 | $7.05 | -68% |
| 2026 YTD | $7.05 | $0.27 | -96% |
CODX has finished five years in a row lower, and it's down 96% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CODX on returns for 2026, with the stronger performance.